Canadian Delegation Visiting Hanmi Bioplant... "Discussing Open Collaboration"

Hanmi Pharmaceutical announced on the 16th that a Canadian delegation consisting of CEOs and key officials from 10 pharmaceutical and biotech companies, including Atuka, Zenvira Bioscience, and Iprogen, visited Hanmi Pharmaceutical's Pyeongtaek Bio Plant on the 9th.

On the 9th, after touring Hanmi Pharmaceutical's Pyeongtaek Bio Plant, the Canadian delegation took a commemorative photo with Hanmi officials. Photo by Hanmi Pharmaceutical

Hanmi Pharmaceutical explained that the delegation's visit was made at the request of the Embassy of Canada in Korea. The delegation visited the Pyeongtaek Bio Plant during 'Bio Korea 2023,' which was held from the 10th to the 12th.

Hanmi Pharmaceutical and the Canadian delegation shared opinions on the current status of the domestic and international bio industry and discussed open collaboration plans in areas of mutual interest. The delegation toured the large-scale manufacturing facilities, including bioreactors with a maximum capacity of 12,500 liters, and the systems capable of operating them at the Pyeongtaek plant.

Jiahu Wang, founder of Zenvira Bioscience, said, "Our company is just entering the growth stage, and seeing the overall process of Hanmi's bio plant and receiving explanations was helpful in many ways." He added, "Above all, I was impressed by the scale and the automation system applied throughout the process, as well as the flexibility to provide customized services according to client demands."

Stefan Gane, CEO of Emuzinia, said, "Not only was the entire process of biopharmaceutical production impressive, but the technology such as automated warehouses was also excellent." He added, "It was notable that service provision tailored to client needs is possible from the first stage of biopharmaceutical production, the cultivation phase."

Hanmi Pharmaceutical's Pyeongtaek Bio Plant has the production capacity to manufacture over 20 million prefilled syringe (PFS) injectors annually based on finished pharmaceutical products. Unlike major domestic contract manufacturing organizations (CMOs) equipped with animal cell culture-based facilities, the Pyeongtaek plant is equipped with manufacturing facilities using microbial culture, enabling rapid and economical mass production of biopharmaceuticals. Additionally, it can manufacture DNA and messenger RNA (mRNA) vaccines on a large scale, which have gained renewed attention since the COVID-19 pandemic.

A Hanmi Pharmaceutical official said, "This year marks the meaningful 60th anniversary of diplomatic relations between Korea and Canada," adding, "We expect more active mutual cooperation between Korean and Canadian pharmaceutical and biotech companies following the Canadian delegation's visit to the Pyeongtaek plant."

Executives from over 10 Canadian pharmaceutical and biotech companies, including Atuka, Zenvira Bioscience, and Iprogen, are touring Hanmi Pharm's Pyeongtaek Bio Plant manufacturing facility.
[Photo by Hanmi Pharm]